Prostaglandin E1: a review.
Work on the structure of prostaglandin E1 (PGE1), isolated from natural sources, was completed 25 years ago (1). Shortly after, methods for the chemical synthesis of PG with their natural configuration were developed in the laboratories of the UpJohn Company (2) and of E. J. Corey (3) and, by the late sixties, PGE1 became widely available. The information since accumulated about its biological and clinical effects is more substantial than for any other PG. This review will draw together some of this information, focusing on recent studies of its mechanisms of action.
D000527:Alprostadil / Q000096:biosynthesis; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D006976:Hypertension, Pulmonary / Q000378:metabolism; D011493:Protein Kinase C / Q000378:metabolism; D011928:Raynaud Disease / Q000378:metabolism; D011982:Receptors, Prostaglandin / Q000378:metabolism; D018078:Receptors, Prostaglandin E; D014652:Vascular Diseases / Q000378:metabolism
D011982:Receptors, Prostaglandin; D018078:Receptors, Prostaglandin E; D000242:Cyclic AMP; D011493:Protein Kinase C; D000527:Alprostadil; D002118:Calcium